iShares iBonds 2031年12月期市政債券ETF IBMT 深 滬
等待開盤 02-10 09:30:00 美东时间
26.28
+0.060
+0.23%
華盛通- 最 高26.33
- 今 開26.27
- 成交量 1.53万股
- 最 低 26.25
- 昨 收 26.22
- 總市值 7621.20万
- 52周最高 26.33
- 市盈率 靜 --
- 換手率 0.53%
- 52周最低 23.7411
- 委 比 13.64%
- 總股本 290.00万
- 歷史最高 26.33
- 量 比 0.78
- 振 幅 0.31%
- 歷史最低 23.7411
- 每 手 1
- 風險率 0.59%
個股概要
財務分析
公司資料
相關新聞
分紅派息
- 分時圖
- 日k
- 周k
- 月k
相關新聞
更多CareDx to Present AlloHeme Pivotal Clinical Validation Data for Hematologic Cancer Relapse Detection at 2026 Tandem Meetings
CareDx to Present AlloHeme Pivotal Clinical Validation Data for Hematologic Cancer Relapse Detection at 2026 Tandem Meetings CareDx Inc. has announced that pivotal clinical validation data from the ACROBAT study evaluating its AlloHeme™ test for hematologic cancer relapse detection will be presented
02-03 20:05
CareDx kündigt Präsentation klinischer Validierungsdaten zum AlloHeme-Test zur Rückfallüberwachung bei Blutkrebspatienten an
CareDx kündigt Präsentation klinischer Validierungsdaten zum AlloHeme-Test zur Rückfallüberwachung bei Blutkrebspatienten an CareDx Inc. hat angekündigt, dass die vollständigen 24-Monats-Ergebnisse der klinischen Validierungsstudie ACROBAT zu AlloHeme™, einem KI-basierten Bluttest zur Überwachung vo
02-03 20:05
Artiva Biotherapeutics to Present Data on AlloNK Cost-Effectiveness and Durability at Tandem Meetings
Artiva Biotherapeutics to Present Data on AlloNK Cost-Effectiveness and Durability at Tandem Meetings Artiva Biotherapeutics Inc. will present at the 2026 Transplantation & Cellular Therapy Meetings of ASTCT and CIBMTR (Tandem Meetings), taking place from February 4 to 7, 2026, in Salt Lake City, Ut
01-21 21:01
Artiva Biotherapeutics Highlights AlloNK Cost-Effectiveness and Durability in New Clinical Trial Data
Artiva Biotherapeutics Highlights AlloNK Cost-Effectiveness and Durability in New Clinical Trial Data Artiva Biotherapeutics Inc. announced upcoming presentations at the 2026 Transplantation & Cellular Therapy Meetings of ASTCT and CIBMTR, scheduled for February 4-7, 2026, in Salt Lake City, Utah. T
01-21 21:00
BRIEF-Beam Therapeutics To Encore Data From Beacon Phase 1/2 Clinical Trial Of Beam-101
Jan 23 (Reuters) - Beam Therapeutics Inc BEAM.O: BEAM THERAPEUTICS TO ENCORE DATA FROM BEACON PHASE 1/2 CLINICAL TRIAL OF BEAM-101 IN SICKLE CELL DISEASE AT 2025 TANDEM MEETINGS OF ASTCT AND CIBMTR So...
2025-01-23 20:01
